Healx Limited

Healx is a Cambridge biotechnology company using its proprietary AI discovery platform to identify new treatment options for rare diseases. Healx has built a pipeline of rare diseases assets and has set an ambitious goal to create 100 new therapeutic opportunities for rare diseases to 2025. Our leading programme in Fragile X is currently phase 2a ready. Other assets are in pre-clinical phase such as Pitt Hopkins and CDKL5. 

Healx also partners with pharma companies and charities to help them build rare diseases portfolios faster. 

Organisation type
Dr Michale Bouskila-Chubb
Head of Business Development